Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Ivacaftor

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

  • Read more about Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

  • Read more about Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment

  • Read more about Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment

Ivacaftor in Cystic Fibrosis With Residual Function: Lung Function Results From an N-of-1 Study

  • Read more about Ivacaftor in Cystic Fibrosis With Residual Function: Lung Function Results From an N-of-1 Study

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

  • Read more about GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

  • Read more about CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.

  • Read more about Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.

Use is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

  • Read more about Use is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

  • Read more about An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)

  • Read more about GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
  • first
  • previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)